Pharmaceuticals Global On demand · 24-48h

Global Qingwen Jiedu Pills Market Strategic Research Report

Global Qingwen Jiedu Pills Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Qingwen Jiedu Pills Market
$45.362025
4.3%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Water Honey Pills, Large Honey Pills

By Application: Hospital, Clinic, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Yantai Bohai Pharmaceutical Group Co., Ltd., Guangshengyuan Chinese Medicine Co., Ltd., Mudanjiang Lingtai Pharmaceutical Co., Ltd., Beijing Tongrentang Co., Ltd., Guangdong Hongxing Group Co., Ltd., Minsheng Pharmaceutical Group Co., Ltd., Shijiazhuang Yuzetang Pharmaceutical Co., Ltd., Jilin Fino Pharmaceutical Co., Ltd., Langzhi Group Shuangren Pharmaceutical Co., Ltd., Shijiazhuang Yuhetang Pharmaceutical Co., Ltd., Xi'an Zili Chinese Medicine Group Co., Ltd., Shandong Hongjitang Pharmaceutical Group Co., Ltd., Henan Baiquan Pharmaceutical Co., Ltd., Heilongjiang Sunflower Pharmaceutical Co., Ltd., Taiyuan Daningtang Pharmaceutical Co., Ltd., Zojinming Pharmaceutical Co., Ltd., Anshan Pharmaceutical Co., Ltd.

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 135 pages
Market size 2025
$45.36
Million USD
Forecast CAGR
4.3%
2025-2032
Forecast 2032
$60.9
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

نظرة عامة

Scope of the Report

The global Qingwen Jiedu Pills market size is predicted to grow from US$ 45.36 million in 2025 to US$ 60.72 million in 2032; it is expected to grow at a CAGR of 4.3% from 2026 to 2032.

Qingwen Jiedu Pills is a traditional Chinese medicine preparation, mainly used to prevent and treat acute respiratory infections such as colds and influenza caused by exogenous wind-heat. It is composed of a variety of Chinese medicinal materials that have the effects of clearing heat and detoxifying, dispersing wind and heat, cooling blood and reducing swelling, such as Forsythia suspensa, Honeysuckle, Isatis root, Scutellaria baicalensis, etc. Qingwen Jiedu Pills regulate the body's immune function and relieve symptoms such as fever, headache, sore throat, and cough. It is suitable for the prevention and treatment of early febrile diseases and influenza.

Global key Qingwen Jiedu Pills players cover Yantai Bohai Pharmaceutical Group Co., Ltd., Guangshengyuan Chinese Medicine Co., Ltd., Mudanjiang Lingtai Pharmaceutical Co., Ltd., Beijing Tongrentang Co., Ltd., Guangdong Hongxing Group Co., Ltd., etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Qingwen Jiedu Pills market?

What factors are driving Qingwen Jiedu Pills market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Qingwen Jiedu Pills market opportunities vary by end market size?

How does Qingwen Jiedu Pills break out by Type, by Application?

This report presents a comprehensive overview of the global Qingwen Jiedu Pills market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Water Honey Pills
  • Large Honey Pills

Segment by Application

  • Hospital
  • Clinic
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Qingwen Jiedu Pills market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hospital, Clinic, Other evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Qingwen Jiedu Pills Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 4.3%
Regional growth momentum
Market share by segment
Key metrics
Base value
$45.36
2025
Forecast
$60.9
2032
CAGR
4.3%
2025–2032
Regions
5
global
Key companies
Yantai Bohai Pharmaceutical Group Co., Ltd.Guangshengyuan Chinese Medicine Co., Ltd.Mudanjiang Lingtai Pharmaceutical Co., Ltd.Beijing Tongrentang Co., Ltd.Guangdong Hongxing Group Co., Ltd.Minsheng Pharmaceutical Group Co., Ltd.Shijiazhuang Yuzetang Pharmaceutical Co., Ltd.Jilin Fino Pharmaceutical Co., Ltd.
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Water Honey PillsLarge Honey Pills
By Application
HospitalClinicOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Water Honey Pills
  • 3.1.3 Large Honey Pills
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hospital
  • 4.1.3 Clinic
  • 4.1.4 Other
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Yantai Bohai Pharmaceutical Group Co., Ltd.
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Guangshengyuan Chinese Medicine Co., Ltd.
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Mudanjiang Lingtai Pharmaceutical Co., Ltd.
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Beijing Tongrentang Co., Ltd.
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Guangdong Hongxing Group Co., Ltd.
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Minsheng Pharmaceutical Group Co., Ltd.
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Shijiazhuang Yuzetang Pharmaceutical Co., Ltd.
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Jilin Fino Pharmaceutical Co., Ltd.
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Langzhi Group Shuangren Pharmaceutical Co., Ltd.
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Shijiazhuang Yuhetang Pharmaceutical Co., Ltd.
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Xi'an Zili Chinese Medicine Group Co., Ltd.
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Shandong Hongjitang Pharmaceutical Group Co., Ltd.
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Henan Baiquan Pharmaceutical Co., Ltd.
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Heilongjiang Sunflower Pharmaceutical Co., Ltd.
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Taiyuan Daningtang Pharmaceutical Co., Ltd.
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Zojinming Pharmaceutical Co., Ltd.
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Anshan Pharmaceutical Co., Ltd.
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global Qingwen Jiedu Pills market size?
The global Qingwen Jiedu Pills market is estimated at US$ 45.36 million in 2025 (base year) and is projected to reach US$ 60.72 million by 2032.
What growth rate is expected for the Qingwen Jiedu Pills market through 2032?
The market is expected to grow at a CAGR of 4.3% from 2026 to 2032, expanding from US$ 45.36 million in 2025 to US$ 60.72 million in 2032, roughly 1.3 times its base-year value.
How is Qingwen Jiedu Pills defined?
Qingwen Jiedu Pills is a traditional Chinese medicine preparation, mainly used to prevent and treat acute respiratory infections such as colds and influenza caused by exogenous wind-heat. It is composed of a variety of Chinese medicinal materials that have the effects of clearing heat and detoxifying, dispersing wind and heat, cooling blood and reducing swelling, such as Forsythia suspensa, Honeysuckle, Isatis root, Scutellaria baicalensis, etc.
What are the main segments of the Qingwen Jiedu Pills market by type?
By type, the market is segmented into Water Honey Pills and Large Honey Pills.
Which applications drive demand in the Qingwen Jiedu Pills market?
Key applications covered include Hospital, Clinic and Other.
Who are the key players in the Qingwen Jiedu Pills market?
Key players profiled include Yantai Bohai Pharmaceutical Group Co., Guangshengyuan Chinese Medicine Co., Mudanjiang Lingtai Pharmaceutical Co., Beijing Tongrentang Co., Guangdong Hongxing Group Co., Minsheng Pharmaceutical Group Co., Shijiazhuang Yuzetang Pharmaceutical Co. and Jilin Fino Pharmaceutical Co., among 17 companies covered in total.
Which regions and countries are covered for Qingwen Jiedu Pills?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Qingwen Jiedu Pills market?
What factors are driving Qingwen Jiedu Pills market growth, globally and by region?
Who should buy the Qingwen Jiedu Pills market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hospital, Clinic and Other, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Qingwen Jiedu Pills market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from ‏3,500.00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.